Numeric Biotech ^Companies

Numeric Biotech is a biopharmaceutical company dedicated to curing rare and debilitating diseases, with a particular focus on age-related diseases where chronic inflammation is a root cause or exacerbates the severity of the disease. Their innovative portfolio includes first-in-class treatments that target multiple mechanisms of age-related diseases, including cancer. Their lead compound, NBT-103, selectively competes with the foxo4-p53 binding in the nucleus of senescent cells, activating malfunctioning mitochondria and resulting in apoptosis of pro-inflammatory producing cells. The efficacy of NBT-103 has been validated by top research institutes in various animal models, demonstrating its potential in treating age-related diseases.